149 related articles for article (PubMed ID: 22068670)
1. Clinical evaluation of leukocyte filtration as an alternative anti-inflammatory strategy to aprotinin in high-risk patients undergoing coronary revascularization.
Farsak B; Gunaydin S; Yildiz U; Sari T; Zorlutuna Y
Surg Today; 2012 Apr; 42(4):334-41. PubMed ID: 22068670
[TBL] [Abstract][Full Text] [Related]
2. Comparison of polymethoxyethylacrylate-coated circuits with leukocyte filtration and reduced heparinization protocol on heparin-bonded circuits in different risk cohorts.
Gunaydin S; McCusker K; Vijay V; Isbir S; Sari T; Onur MA; Gurpinar A; Sezgin A; Sargon MF; Tezcaner T; Zorlutuna Y
Perfusion; 2006 Nov; 21(6):329-42. PubMed ID: 17312857
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy of two-phase leukocyte filtration in high-risk patients undergoing coronary revascularization with cardiopulmonary bypass.
Gunaydin S; Modine T; Sari T; Zorlutuna Y; Gourlay T
J Extra Corpor Technol; 2009 Sep; 41(3):149-56. PubMed ID: 19806797
[TBL] [Abstract][Full Text] [Related]
4. Hyaluronan based heparin free coated open and closed extracorporeal circuits for high risk coronary revascularization.
Gunaydin S; Ucar HI; Serter T; McCusker K; Ozcelik G; Salman N; Yorgancioglu AC
J Extra Corpor Technol; 2010 Dec; 42(4):286-92. PubMed ID: 21313926
[TBL] [Abstract][Full Text] [Related]
5. Clinical and biomaterial evaluation of a new condensed dual-function extracorporeal circuit in reoperation for coronary artery bypass surgery.
Gunaydin S; McCusker K; Vijay V
Int J Artif Organs; 2009 Nov; 32(11):802-10. PubMed ID: 20020412
[TBL] [Abstract][Full Text] [Related]
6. Clinical and biomaterial evaluation of hyaluronan-based heparin-bonded extracorporeal circuits with reduced versus full systemic anticoagulation in reoperation for coronary revascularization.
Gunaydin S; Farsak B; McCusker K; Vijay V; Sari T; Onur MA; Gurpinar A; Zorlutuna Y
J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):135-42. PubMed ID: 19377380
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy of leukofiltration on cardiopulmonary bypass related inflammatory response: Fact or Foe?
Kiliç D; Gunaydin S; Kisa U; Sari T; Deveci O; Zorlutuna Y
Inflamm Res; 2009 Jun; 58(6):292-7. PubMed ID: 19266265
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of minimized extracorporeal circulation in high-risk coronary revascularization: impact on air handling, inflammation, hemodilution and myocardial function.
Gunaydin S; Sari T; McCusker K; Schonrock U; Zorlutuna Y
Perfusion; 2009 May; 24(3):153-62. PubMed ID: 19755462
[TBL] [Abstract][Full Text] [Related]
9. The importance of aprotinin and pentoxifylline in preventing leukocyte sequestration and lung injury caused by protamine at the end of cardiopulmonary bypass surgery.
Ege T; Arar C; Canbaz S; Cikirikcioglu M; Sunar H; Yuksel V; Duran E
Thorac Cardiovasc Surg; 2004 Feb; 52(1):10-5. PubMed ID: 15002070
[TBL] [Abstract][Full Text] [Related]
10. 'High dose' aprotinin and heparin-coated circuits: clinical efficacy and inflammatory response.
Parolari A; Alamanni F; Gherli T; Salis S; Spirito R; Foieni F; Rossi F; Bertera A; Oddono P; Biglioli P
Cardiovasc Surg; 1999 Jan; 7(1):117-27. PubMed ID: 10073771
[TBL] [Abstract][Full Text] [Related]
11. Clinical performance and biocompatibility of hyaluronan-based heparin-bonded extracorporeal circuits in different risk cohorts.
Gunaydin S; McCusker K; Sari T; Onur MA; Zorlutuna Y
Interact Cardiovasc Thorac Surg; 2010 Mar; 10(3):371-6. PubMed ID: 20026488
[TBL] [Abstract][Full Text] [Related]
12. Leukocyte integrin expression in patients undergoing cardiopulmonary bypass.
Asimakopoulos G; Kohn A; Stefanou DC; Haskard DO; Landis RC; Taylor KM
Ann Thorac Surg; 2000 Apr; 69(4):1192-7. PubMed ID: 10800818
[TBL] [Abstract][Full Text] [Related]
13. Reducing the post-pump syndrome by using heparin-coated circuits, steroids, or aprotinin.
Harig F; Feyrer R; Mahmoud FO; Blum U; von der Emde J
Thorac Cardiovasc Surg; 1999 Apr; 47(2):111-8. PubMed ID: 10363611
[TBL] [Abstract][Full Text] [Related]
14. Clinical performance and biocompatibility of novel hyaluronan-based heparin-bonded extracorporeal circuits.
Gunaydin S; Mccusker K; Vijay V
J Extra Corpor Technol; 2005 Sep; 37(3):290-5. PubMed ID: 16350383
[TBL] [Abstract][Full Text] [Related]
15. Strategic leukocyte depletion reduces pulmonary microvascular pressure and improves pulmonary status post-cardiopulmonary bypass.
Olivencia-Yurvati AH; Ferrara CA; Tierney N; Wallace N; Mallet RT
Perfusion; 2003 Mar; 18 Suppl 1():23-31. PubMed ID: 12708762
[TBL] [Abstract][Full Text] [Related]
16. Leukocyte filtration and aprotinin: synergistic anti-inflammatory protection.
Olivencia-Yurvati AH; Wallace N; Ford S; Mallet RT
Perfusion; 2004; 19 Suppl 1():S13-9. PubMed ID: 15161060
[TBL] [Abstract][Full Text] [Related]
17. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
[TBL] [Abstract][Full Text] [Related]
18. Cardioprotective effect of aprotinin on myocardial ischemia/reperfusion injury during cardiopulmonary bypass.
Karaca P; Konuralp C; Enc Y; Süzer A; Sokullu O; Ayoglu U; Cicek S
Circ J; 2006 Nov; 70(11):1432-6. PubMed ID: 17062966
[TBL] [Abstract][Full Text] [Related]
19. Does aprotinin reduce lung reperfusion damage after cardiopulmonary bypass?
Rahman A; Ustünda B; Burma O; Ozercan IH; Cekirdekçi A; Bayar MK
Eur J Cardiothorac Surg; 2000 Nov; 18(5):583-8. PubMed ID: 11053821
[TBL] [Abstract][Full Text] [Related]
20. Effects of methylprednisolone and aprotinin on phospholipase D activity of leukocytes in systemic inflammatory response induced by cardiopulmonary bypass.
Wu M; Lu YB; Jiang B; Xu SW; Chen RK; Zhou HL
Acta Pharmacol Sin; 2001 Oct; 22(10):913-7. PubMed ID: 11749774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
